Eli Lilly (LLY) shares fell almost 4% in recent trading Monday after the Trump administration decided to table a plan allowing Medicare to pay for anti-obesity medications, which would have granted more people access to the company's weight-loss drug Zepbound.
The Centers for Medicare & Medicaid Services said Friday it was not finalizing the provision in the proposed rule at this time, but may address it in the future.
A Lilly spokesperson said Medicare's decision was not the best interpretation of the Part D Coverage provision of the rule and will impacts the access to obesity treatment.
"We will continue to work with the Trump Administration and Congressional leaders to ensure people living with obesity are covered by Medicare and Medicaid and are no longer left behind," the spokesperson said.
Price: 709.32, Change: -28.89, Percent Change: -3.91
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.